NCT07746089 — Congenital Myasthenic Syndrome trial site landscape

Public-registry site landscape for NCT07746089, “A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS)”, a Congenital Myasthenic Syndrome study sponsored by argenx. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT07746089 (registry record)
Study title	A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS)
Official title	Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4-CMS
Sponsor	argenx
Condition(s)	Congenital Myasthenic Syndrome; CMS
Phase	PHASE3
Listed sites	0

Patient-friendly overview of this study: eichor.com/study/NCT07746089.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT07746089 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →